New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
11:20 EDTVNDAVanda shares attractive amid negative sentiment, says Piper Jaffray
Piper Jaffray believes the negative sentiment surrounding shares of Vanda Pharmaceuticals presents an excellent entry point into the name. Piper says Vanda has yet to ramp its physician education efforts regarding Hetlioz and that the dug has the potential to be a multi-hundred million dollar product. The firm reiterates an Overweight rating on Vanda with a $21 price target.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 5, 2015
07:19 EDTVNDAVanda's Hetlioz shows sleep parameter improvements in Phase II trial
Vanda Pharmaceuticals announced publication of pivotal trial results related to patient entrainment in the August issue of The Lancet. The published trial results are from the SET and RESET Phase III studies of Hetlioz, a circadian regulator for the treatment of individuals suffering from Non-24, a serious, rare and chronic circadian rhythm disorder that affects a majority of totally blind individuals who cannot entrain their master body clock to the 24-hour day. Tasimelteon, marketed under the tradename Hetlioz, is currently approved for use in the U.S. and the EU. Hetlioz achieved the primary endpoints of entrainment of the melatonin rhythm as compared to placebo and clinical response as measured by entrainment plus a score of greater than or equal to 3 on the Non-24 Clinical Response Scale. Hetlioz also demonstrated significant improvement versus placebo across a number of sleep and wake parameters. Patients treated with Hetlioz maintained their clinical benefits while patients who received placebo showed significant deterioration in measures of nighttime sleep, daytime sleep and timing of sleep.
August 3, 2015
07:02 EDTVNDAVanda's new four Fanapt patents listed in FDA publication
Subscribe for More Information
July 29, 2015
19:32 EDTVNDAOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTVNDAVanda raises FY15 Hetlioz, Fanapt sales to $100M-$115M from $95M-$110M
FY15 revenue consensus is $104.18M. Sees Hetlioz sales $40M-$45M. Raises Fanapt sales to $60M-$70M from $55M-$65M.
16:18 EDTVNDAVanda reports Q2 adjusted EPS (1c), may not compare to two estimates (29c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use